March 23rd, 2016 – 1:00pm-4:00pm, 155 Gibbs Street, Rockville, MD
Hear from the exciting companies completing the first Relevant Health cohort! This event is currently invite only, but if you would like to find out more and possibly attend please send an email to info@relevanthealth.md
To find out more about the cohort, visit http://www.relevanthealth.md/companies.html
You thought the Shark Tank was tough… wait until you enter the the first annual Maryland Crab Trap!
Submit your application to our business plan competition for a chance to be named the company with the most commercial potential at the Regional Biotech Forum and have the opportunity to win $10,000 and an incubation space! Pitch your idea to industry experts on April 19th and 5 Finalists will have the chance to win the Grand Prize. This competition will be focused on companies in the following sectors: Therapeutics, Diagnostics, Medical Devices, Healthcare Services, E-Health, Mobile Health, Electronic Medical Records, Health Informatics, and BioHealth Cyber Security.
Companies will be scored on: Product, Technical Feasibility, Marketing/Strategy, and Leadership team.
Deadline for entries is March 25th – Finalists will be announced by April 4th -Regional Biotech Forum Event: Panel Presentation is on April 18th
The Intramural Research Program of the National Institutes of Health (NIH) is seeking an outstanding individual to serve as Director of the Office of Technology Transfer (OTT), Office of Intramural Research, Office of the Director. The OTT provides support to the technology transfer functions of the NIH Institutes and Centers (ICs) that manage the patenting and licensing of inventions made by scientists in the NIH intramural research program. The OTT is responsible for negotiating amendments to these licenses and for patent license enforcement activities. OTT also manages the administration of royalties ($138M in FY2014), which are distributed to inventors, ICs where the inventions were made, and to co-inventors under Inter-Institutional Agreements. OTT manages multiple IT systems which track the NIH invention lifecycle including data and documentation workflows. It manages the docketing of all patent correspondence from contract law firms, receiving and processing new invention disclosures, marketing of NIH licensing opportunities, central reporting of NIH-wide technology transfer data, and necessary training in the use of the centralized database. The incumbent has overall responsibility for strategic and tactical operational planning, and financial management for the OTT. The Director of OTT reports to the Deputy Director for Intramural Research, NIH.
Maryland-based biotechnology firm MaxCyte Inc Thursday said it plans to list on London’s AIM market later this month.
The company expects to be admitted to AIM March 29, and plans to raise GBP10 million on admission. It expects to have a GBP30.4 million market capitalisation.
Congratulations to Montgomery County Innovation Network Director John Korpela for receiving a service award from the Maryland Business Incubator Association on March 4 at the Germantown Innovation Center during its annual meeting. The award was presented by MBIA President Robert Snyder and recognizes John for his 12 years of service, leadership, and mentorship.
Inner Harbor is the latest site of a new Baltimore incubator.
With Harbor Launch, the Institute of Marine and Environmental Technology (IMET) has designated areas of office and lab space specifically for biotech and environmental startups at Columbus Center (the big building with the sails on it near Pier Five).
Every year in March, Women In Bio celebrates Women’s History Month (WHM) with events highlighting the most pressing issues for women in the biosciences/technology field. This year’s theme is “Expanding the 50-50 Challenge,” and our WIB-DC/Baltimore chapter WHM event will identify opportunities, barriers, and challenges for women who are becoming investors in their own right, as well as challenges for women entrepreneurs to access investment. On a broader note, our panel will discuss how women can identify and tackle with gender disparities in the professional environment through “investing” in their own and their female colleague’s professional goals.
Companies founded on technology licensed from Johns Hopkins University have raised $1 billion since 2010. And 90 percent of those companies are no longer in Maryland.
Christy Wyskiel, who leads Johns Hopkins Technology Ventures, the university’s commercialization arm, hopes to reverse that trend with a new partnership with Village Capital and the Abell Foundation.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received U.S. Food and Drug Administration (FDA) approval for its BD Totalys MultiProcessor and BD Totalys SlidePrep instruments.
The Institute for Bioscience and Biotechnology Research (IBBR) is interested in proposals to lease a bio-manufacturing facility configured to produce biologicals under cGMP conditions in compliance with FDA requirements for phase I/II clinical trials. The facility is also equipped to perform process development research, preclinical manufacturing for material necessary for IND-enabling toxicology studies, Point of Concept (POC) studies, and process demonstration in advance of GMP manufacturing. The Good Manufacturing Practices (GMP) facility is located on the University of Maryland’s Shady Grove campus at 9600 Gudelsky Drive, Rockville, MD 20850.
Where: Relevant Health 155 Gibbs St. #529 Rockville, MD 20850
Join us for an evening of networking around innovation and commercialization at the BioBuzz @ Relevant Health. Meet with the organizations fueling commercialization in Maryland – BHI & TEDCO – and mingle with the first cohort of companies in the regions newest BioHealth accelerator – Relevant Health.
BHI, who operates the relevant health accelerator, is an innovation intermediary focused on commercializing market-relevant bio-health innovations and increasing access to early-stage funding. This is your chance to get to know some of their TEAM and Entrepreneur’s in Residence to help you bring your product to market.
This event will be TEDCO’s bi-monthly “meet the program managers” event. Take this opportunity mingle with the program managers and learn about how you can navigate through TEDCO’s funding programs. TEDCO is State’s go-to resource for funding start-ups that need guidance as they bring innovative concepts to market.
As venture capitalists focus more on bigger deals, a growing demand is developing for business accelerators and incubators to fund startups, Dreamit Ventures LLC CEO Avi Savar said Saturday at South By Southwest.
To identify today’s top venture investors, CB Insights, a research firm that tracks the venture capital industry, created a data-driven list. The firm based its report on factors like connectedness, since people with access to the best information hear about hot companies first, and exits, meaning the returns generated when a start-up is sold or goes public. For exits, the firm considered the valuation and when the investor first put money into the company.
Health Wildcatters got recognized for the first time in an annual report ranking seed accelerators. It scored a Silver ranking while Healthbox attained a Gold in the Seed Accelerator Rankings Project.
Hubert Zajicek is the head of the Dallas-based Wildcatters accelerator, which has been around since 2012. It has 32 portfolio companies and is currently looking for applicants for its Fall class later this year.
South Korean venture capital companies turn their eyes to promising biotech firms overseas, looking for a vehicle to accelerate their investment goals.
KTB Network recently joined hands with three Chinese venture capital companies to invest a total of 36 billion won ($30.1 million) in the country’s biopharma company CARsgen Therapeutics. The biotech company is highly praised for its immune cell therapy platform. It is working on a new method to treat patients with glioblastoma and hepatocellular carcinoma with a goal to conduct a clinical trial next year.
Becton Dickinson’s (NYSE:BDX) decision to spin off its respiratory devices into a joint venture with Apax Partners will allow it to offload an underperforming segment and concentrate on its core business of diagnostics. And the agreement also highlights the growing involvement of private equity in the medtech industry.
J. Craig Venter, Ph.D., is regarded as one of the leading scientists of the 21st century for his numerous contributions to genomic research. In addition to his past key positions, he is founder, current chairman, and CEO of the J. Craig Venter Institute (JCVI), a not-for-profit, research organization dedicated to human, microbial, plant, synthetic, and environmental genomic research, and the exploration of social and ethical issues in genomics.
A University of Maryland startup is among the finalists in Under Armour CEO Kevin Plank’s Cupid’s Cup, a competition offering a $100,000 prize of the winner.
Angel investment funding in healthcare increased in 2015, compared with the previous years, according to a new report from the Angel Resource Institute and PitchBook. The 2015 Annual Halo Report found that healthcare deals accounted for 23 percent of angel investment.
When Inova Health System announced it would create a $100 million venture fund— unveiled as part of a splashy White House event last month highlighting precision medicine investments— it was just the kind revelation Inova has gotten so good at making in the last year.
Heart disease, cancer, diabetes, obesity, arthritis—chronic conditions such as these account for 84% of health care spending. Yet many are preventable. An estimated 40% of all premature deaths can be attributed to lifestyle, such as smoking and inactivity. How can the health care system shift focus (and dollars) from acute to preventative care?
Almost every day, we see announcements about yet another “connected” product that is hailed as creating a “smarter” home environment. These types of products promise an easier, more convenient way of living, but they aren’t always connected to our lives—or all that smart.
Pittsburgh-area entrepreneurs will soon have another funding option for growing early phase startup companies.
Pharmaceutical giant GlaxoSmithKline has thrown its support behind the creation of a $100 million venture capital fund, which will help meet a need for early stage business startup capital in the Pittsburgh area. Philadelphia-based SG3 Ventures anticipates awarding its first round of funding in about a year, according to Brian McVeigh, vice president of worldwide business development transactions and investment management at GSK.
For the last few years, the spotlight in start-up investing has largely shone on those who poured money into a company when it was already well along on a growth path. It turns out that spotlight may have been misdirected.
The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
